<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02887677</url>
  </required_header>
  <id_info>
    <org_study_id>ESR-15-10964</org_study_id>
    <nct_id>NCT02887677</nct_id>
  </id_info>
  <brief_title>Effects of Dapagliflozin on Central Hemodynamics and Urine Albumin Excretion in Patients With Type 2 Diabetes.</brief_title>
  <official_title>A Study of the Effects of Dapagliflozin on Ambulatory Aortic Pressure, Arterial Stiffness and Urine Albumin Excretion in Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hellenic Society for Medical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hellenic Society for Medical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the hypothesis that the treatment-induced reductions in the
      ambulatory aortic pressure are more pronounced in the group of dapagliflozin than in the
      group of placebo.

      It is a 12 week, double-blind, randomized, placebo-controlled clinical trial of dapagliflozin
      versus placebo in 160 adult patients with type 2 diabetes mellitus (DM). It will be conducted
      in three centers.

      Potentially eligible patients will be asked to provide written informed consent (Screening
      Visit). Patients, who fulfill the inclusion and exclusion criteria, will be asked to visit
      the sites one week (Visit 1 - V1) after the screening visit. On Visit 2 (V2) all eligible
      patients will be randomized to one of the two treatment arms and will continue with the next
      visits as appropriate (Visit 3, Telephone Visit 1, Visit 4-end of study).

      Aortic blood pressure (BP) and arterial stiffness parameters will be measured as indicated by
      the protocol in V1 and V3 with the Mobil-O-Graph monitor.

      Blood samples will be collected as indicated by the protocol in Screening Visit for the
      measurement of glycated hemoglobin (HbA1c), creatinine and liver function parameters. In
      addition, blood samples will be collected in V1 and V3 for routine hematological and
      biochemical tests including creatinine, fasting glucose, HbA1c, lipid profile and liver
      function parameters.

      Urine samples will be collected as indicated by the protocol in V1 and V3 for the measurement
      of albumin to creatinine ratio.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design

      Screening visit: Potentially eligible patients will be asked to provide written informed
      consent. The investigators will record full medical history, clinical examination,
      demographic characteristics, electrocardiogram (ECG), body weight, height, body mass index
      (BMI) and waist perimeter. Office blood pressure (BP) will be measured by the physicians
      three times using a mercury sphygmomanometer [cuffs will be placed at the level of brachial
      artery and a three minute interval will intercept each measurement, following 10 minutes of
      rest in the seated position (the cuff will cover at least 80% of the brachial circumference
      and 2/3 of the brachial length.)]. The investigators will also collect blood samples to
      determine glycated hemoglobin (HbA1C), creatinine, glomerular filtration rate (GFR) and liver
      function.

      Visit 1 (V1): Patients, who fulfill the inclusion and exclusion criteria, will be asked to
      visit the sites 1 week after the screening visit (+/-2 days), following a 12-hour fast. Three
      measurements of office BP at the level of brachial artery, with a three minutes interval
      between each measurement, will be performed with the use of a mercury sphygmomanometer, after
      10 minutes-rest in the sitting posture (cuff with bladder size encircling at least 80% of arm
      circumference and covering two thirds of arm length). After that, venous blood specimens and
      a spot urine specimen will be collected for relevant blood tests and albumin/creatinine ratio
      (ACR) respectively. Subsequently, the Mobil-O-Graph monitor with a cuff of appropriate size
      will be fitted and the BP recording will be initiated for 24 hours. The device will be
      programmed to collect data every 20 minutes, except for 23:00 to 07:00 (data collection every
      30 minutes).

      Visit 2 (V2): An appointment will be scheduled the following day for the patient to drop-off
      the Mobil-O-Graph device. Patients will be randomized in a 1:1 ratio to the dapagliflozin or
      placebo group and will start receiving the drug regimen the same day. Moreover, all patients
      will receive dietary and lifestyle advice commencing from this visit.

      Telephone Visit 1 (ΤV1): A telephone visit (TV1) will be scheduled 6 weeks after V2 (+/-2
      days). Patient history will be obtained, emphasizing on possible adverse events during the
      previous 6 weeks. Home blood glucose levels, if available, would be also discussed.

      Visit 3 (V3): Visit 3 will be scheduled 6 weeks after telephone visit 1 (TV1) (+/-2 days).
      The following parameters will be determined: medical history of the last weeks, clinical
      examination (including three brachial BP measurements with a mercury sphygmomanometer as
      mentioned before), venous blood specimen collection (under 12-hour fast) and the initiation
      of 24-hour ambulatory blood pressure monitoring (ABPM) (Mobil-O-Graph device). The patients
      will also provide a spot urine specimen for ACR evaluation.

      Visit 4 (V4): Visit 4 will be scheduled 1 day after visit 3. Patients will drop-off the
      Mobil-O-Graph device.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>October 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ambulatory systolic aortic pressure</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ambulatory aortic (central) diastolic blood pressure (DBP)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory brachial systolic blood pressure (SBP) and DBP</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory augmentation index (AIx)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory pulse wave velocity (PWV)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Office brachial SBP and DBP</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Albumin/creatinine ratio (ACR)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile (Total-Cholesterol, LDL-Cholesterol, HDL-Cholesterol, triglycerides)</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dapagliflozin for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for oral administration. Patients will be randomized in a 1:1 ratio to the dapagliflozin or placebo group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <description>Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <other_name>Forxiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18 and &lt;70 years old

          -  Type 2 diabetes mellitus

          -  Glycated hemoglobin &gt;7% and &lt;9%

          -  Patients on stable dose of metformin of at least 1500 mg for the past 3 months.

          -  Patient to provide informed consent

        Exclusion Criteria:

          -  Hypovolemic patients.

          -  Patients on loop diuretics.

          -  Patients with low BP (office SBP &lt;110 mmHg) or orthostatic hypotension (BP drop &gt;20
             mmHg and SBP &lt;110 mmHg in standing position at 1 min).

          -  Patients on antidiabetic drugs other than metformin.

          -  Secondary hypertension.

          -  Stage 2 hypertension or higher (office SBP ≥160 mmHg or DBP ≥100 mmHg).

          -  Chronic kidney disease stage 3 or higher (GFR&lt;60 mL/min/1.73 m2).

          -  Myocardial infarction or unstable angina episode within the past 3 months, or
             congestive heart failure class III-IV according to New York Heart Association
             criteria.

          -  Pregnancy or childbearing potential [defined as women which have entered menses and
             are not post-menopausal (menopause is defined as the absence of menses for at least 12
             months without any other medical cause in women of typical age) or women that have
             been subjected to permanent sterilization (ie. tubal ligation, hysterectomy, bilateral
             oophorectomy or bilateral salpingectomy)].

          -  History of liver disease or significant abnormal liver function defined as aspartate
             aminotransferase (AST) &gt;3x upper limit of normal (ULN) and/or alanine aminotransferase
             (ALT) &gt;3x ULN or total bilirubin &gt;2.0 mg/dL.

          -  History of malignancy of any organ system (resected basal cell carcinoma considered
             cured is exempted) within the past 5 years prior to Visit 1 (V1).

          -  History of drug or alcohol abuse within the last one year.

          -  Any contraindication or history of hypersensitivity to the study drug or to drugs with
             similar chemical structures.

          -  Any other surgical or medical condition that, in the opinion of the investigator,
             place the patient at higher risk from his/her participation in the study, or are
             likely to prevent the patient from complying with the requirements of the study or
             completing the trial period.

          -  Intake of an investigational drug in another trial within 30 days prior to Visit 1
             (V1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pantelis Sarafidis</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <overall_contact>
    <last_name>Asterios Karagiannis</last_name>
    <phone>+306972011271</phone>
    <email>astkar@med.auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ahepa Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54621</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kalliopi Kotsa</last_name>
      <phone>+306932045201</phone>
      <email>kalli@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Elena Aggeloudi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hippokrateio Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Asterios Karagiannis</last_name>
      <phone>+306972011271</phone>
      <email>astkar@med.auth.gr</email>
    </contact>
    <investigator>
      <last_name>Antonios Lazaridis</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Papageorgiou Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56429</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christos Manes</last_name>
      <phone>+306955095530</phone>
      <email>maneschr@otenet.gr</email>
    </contact>
    <investigator>
      <last_name>Despoina Kosmidou</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eleonora Kella</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007. Epub 2009 Nov 6.</citation>
    <PMID>19896746</PMID>
  </reference>
  <reference>
    <citation>Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011 Jun;34(6):1249-57. doi: 10.2337/dc11-0442.</citation>
    <PMID>21617109</PMID>
  </reference>
  <reference>
    <citation>Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014 Aug 15;5(4):444-70. doi: 10.4239/wjd.v5.i4.444. Review.</citation>
    <PMID>25126392</PMID>
  </reference>
  <reference>
    <citation>Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, Rand L, Siebert C. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30;329(14):977-86.</citation>
    <PMID>8366922</PMID>
  </reference>
  <reference>
    <citation>Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diab Rep. 2012 Jun;12(3):230-8. doi: 10.1007/s11892-012-0275-6. Review.</citation>
    <PMID>22528597</PMID>
  </reference>
  <reference>
    <citation>Aylsworth A, Dean Z, VanNorman C, Nkemdirim Okere A. Dapagliflozin for the Treatment of Type 2 Diabetes Mellitus. Ann Pharmacother. 2014 Sep;48(9):1202-1208. Epub 2014 Jun 20. Review.</citation>
    <PMID>24951310</PMID>
  </reference>
  <reference>
    <citation>Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-95. doi: 10.2337/db09-9028.</citation>
    <PMID>19336687</PMID>
  </reference>
  <reference>
    <citation>Karagiannis A, Tziomalos K, Anagnostis P, Gossios TD, Florentin M, Athyros VG, Mikhailidis DP. The effect of antihypertensive agents on insulin sensitivity, lipids and haemostasis. Curr Vasc Pharmacol. 2010 Nov;8(6):792-803. Review.</citation>
    <PMID>20626344</PMID>
  </reference>
  <reference>
    <citation>Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012 Jun;35(6):1364-79. doi: 10.2337/dc12-0413. Epub 2012 Apr 19. Review. Erratum in: Diabetes Care. 2013 Feb;36(2):490.</citation>
    <PMID>22517736</PMID>
  </reference>
  <reference>
    <citation>Pandey R, Kumar N, Yadav M, Nagpal R, Jain S, Yadav H. Anti-diabetic compounds and their patent information: an update. Recent Pat Inflamm Allergy Drug Discov. 2013 Jan 1;7(1):35-48. Review.</citation>
    <PMID>23016523</PMID>
  </reference>
  <reference>
    <citation>Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012 Mar 12;344:e1369. doi: 10.1136/bmj.e1369.</citation>
    <PMID>22411919</PMID>
  </reference>
  <reference>
    <citation>Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008 Jan;31(1):81-6. Epub 2007 Oct 12.</citation>
    <PMID>17934153</PMID>
  </reference>
  <reference>
    <citation>Xu X, Wang G, Zhou T, Chen L, Chen J, Shen X. Novel approaches to drug discovery for the treatment of type 2 diabetes. Expert Opin Drug Discov. 2014 Sep;9(9):1047-58. doi: 10.1517/17460441.2014.941352. Epub 2014 Jul 23. Review.</citation>
    <PMID>25054271</PMID>
  </reference>
  <reference>
    <citation>Tasyurek HM, Altunbas HA, Balci MK, Sanlioglu S. Incretins: their physiology and application in the treatment of diabetes mellitus. Diabetes Metab Res Rev. 2014 Jul;30(5):354-71. doi: 10.1002/dmrr.2501. Review.</citation>
    <PMID>24989141</PMID>
  </reference>
  <reference>
    <citation>DeFronzo RA, Davidson JA, Del Prato S. The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. Diabetes Obes Metab. 2012 Jan;14(1):5-14. doi: 10.1111/j.1463-1326.2011.01511.x. Review.</citation>
    <PMID>21955459</PMID>
  </reference>
  <reference>
    <citation>Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch. 2004 Feb;447(5):510-8. Epub 2003 May 14. Review. Erratum in: Pflugers Arch. 2004 Feb;447(5):813-5.</citation>
    <PMID>12748858</PMID>
  </reference>
  <reference>
    <citation>Vlotides G, Mertens PR. Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease. Nephrol Dial Transplant. 2015 Aug;30(8):1272-6. doi: 10.1093/ndt/gfu299. Epub 2014 Sep 17. Review.</citation>
    <PMID>25230708</PMID>
  </reference>
  <reference>
    <citation>Chao EC, Henry RR. SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010 Jul;9(7):551-9. doi: 10.1038/nrd3180. Epub 2010 May 28. Review.</citation>
    <PMID>20508640</PMID>
  </reference>
  <reference>
    <citation>Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005 Dec;54(12):3427-34.</citation>
    <PMID>16306358</PMID>
  </reference>
  <reference>
    <citation>Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. Review.</citation>
    <PMID>24348059</PMID>
  </reference>
  <reference>
    <citation>Albarrán OG, Ampudia-Blasco FJ. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes]. Med Clin (Barc). 2013 Sep;141 Suppl 2:36-43. doi: 10.1016/S0025-7753(13)70062-9. Review. Spanish.</citation>
    <PMID>24444523</PMID>
  </reference>
  <reference>
    <citation>Sun YN, Zhou Y, Chen X, Che WS, Leung SW. The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials. BMJ Open. 2014 Apr 7;4(4):e004619. doi: 10.1136/bmjopen-2013-004619. Review.</citation>
    <PMID>24710132</PMID>
  </reference>
  <reference>
    <citation>Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, Bekiari E, Sarigianni M, Matthews DR, Tsapas A. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2013 Aug 20;159(4):262-74. doi: 10.7326/0003-4819-159-4-201308200-00007. Review.</citation>
    <PMID>24026259</PMID>
  </reference>
  <reference>
    <citation>Sarafidis PA, Georgianos PI, Lasaridis AN. Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opin Drug Saf. 2010 Mar;9(2):243-57. doi: 10.1517/14740330903499240. Review.</citation>
    <PMID>20095917</PMID>
  </reference>
  <reference>
    <citation>Sarafidis PA, Bakris GL. State of hypertension management in the United States: confluence of risk factors and the prevalence of resistant hypertension. J Clin Hypertens (Greenwich). 2008 Feb;10(2):130-9. Review.</citation>
    <PMID>18256578</PMID>
  </reference>
  <reference>
    <citation>Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J; STAR Investigators. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Diabetes Care. 2006 Dec;29(12):2592-7. Erratum in: Diabetes Care. 2007 May;30(5):1329.</citation>
    <PMID>17130190</PMID>
  </reference>
  <reference>
    <citation>Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010 Oct;33(10):2217-24. doi: 10.2337/dc10-0612. Epub 2010 Jun 21.</citation>
    <PMID>20566676</PMID>
  </reference>
  <reference>
    <citation>Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, Parikh S; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012 Mar 20;156(6):405-15. doi: 10.7326/0003-4819-156-6-201203200-00003.</citation>
    <PMID>22431673</PMID>
  </reference>
  <reference>
    <citation>Nauck MA, Del Prato S, Durán-García S, Rohwedder K, Langkilde AM, Sugg J, Parikh SJ. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014 Nov;16(11):1111-20. doi: 10.1111/dom.12327. Epub 2014 Jul 10.</citation>
    <PMID>24919526</PMID>
  </reference>
  <reference>
    <citation>Karagiannis A, Hatzitolios AI, Athyros VG, Deligianni K, Charalambous C, Papathanakis C, Theodosiou G, Drakidis T, Chatzikaloudi V, Kamilali C, Matsiras S, Matziris A, Savopoulos C, Baltatzi M, Rudolf J, Tziomalos K, Mikhailidis DP. Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J. 2009 May 5;3:26-34. doi: 10.2174/1874192400903010026.</citation>
    <PMID>19557149</PMID>
  </reference>
  <reference>
    <citation>Gorostidi M, Vinyoles E, Banegas JR, de la Sierra A. Prevalence of white-coat and masked hypertension in national and international registries. Hypertens Res. 2015 Jan;38(1):1-7. doi: 10.1038/hr.2014.149. Epub 2014 Oct 16. Review.</citation>
    <PMID>25319601</PMID>
  </reference>
  <reference>
    <citation>Clement DL, De Buyzere ML, De Bacquer DA, de Leeuw PW, Duprez DA, Fagard RH, Gheeraert PJ, Missault LH, Braun JJ, Six RO, Van Der Niepen P, O'Brien E; Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003 Jun 12;348(24):2407-15.</citation>
    <PMID>12802026</PMID>
  </reference>
  <reference>
    <citation>Weber MA, Mansfield TA, Alessi F, Iqbal N, Parikh S, Ptaszynska A. Effects of dapagliflozin on blood pressure in hypertensive diabetic patients on renin-angiotensin system blockade. Blood Press. 2016;25(2):93-103. doi: 10.3109/08037051.2015.1116258. Epub 2015 Dec 1. Erratum in: Blood Press. 2016 Aug;25(4):x.</citation>
    <PMID>26623980</PMID>
  </reference>
  <reference>
    <citation>Weber MA, Mansfield TA, T'joen C, Ptaszynska A (2013) Dapagliflozin for Reduction of Blood Pressure in Diabetic Patients Inadequately Controlled With Combination Antihypertensive Regimen. Circulation, 128; A13165.</citation>
  </reference>
  <reference>
    <citation>Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab. 2013 Sep;15(9):853-62. doi: 10.1111/dom.12127. Epub 2013 Jun 5.</citation>
    <PMID>23668478</PMID>
  </reference>
  <reference>
    <citation>Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010 Aug;31(15):1865-71. doi: 10.1093/eurheartj/ehq024. Epub 2010 Mar 2. Review.</citation>
    <PMID>20197424</PMID>
  </reference>
  <reference>
    <citation>Tziomalos K, Athyros VG, Karagiannis A. Treating Arterial Stiffness in Young and Elderly Patients with the Metabolic Syndrome. Curr Pharm Des. 2014;20(39):6106-13. Review.</citation>
    <PMID>24745924</PMID>
  </reference>
  <reference>
    <citation>Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, Kloch-Badełek M, Wiliński J, Curyło AM, Dudek D; Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension. 2008 Apr;51(4):848-55. doi: 10.1161/HYPERTENSIONAHA.107.101725. Epub 2008 Feb 11.</citation>
    <PMID>18268136</PMID>
  </reference>
  <reference>
    <citation>Katsiki N, Koumaras C, Athyros VG, Karagiannis A. Thinking beyond traditional cardiovascular risk factors: the role of arterial stiffness in targeting residual risk. Angiology. 2012 Jan;63(1):9-11. doi: 10.1177/0003319711406256.</citation>
    <PMID>22144689</PMID>
  </reference>
  <reference>
    <citation>Koumaras C, Tzimou M, Stavrinou E, Griva T, Gossios TD, Katsiki N, Athyros VG, Mikhailidis DP, Karagiannis A. Role of antihypertensive drugs in arterial 'de-stiffening' and central pulsatile hemodynamics. Am J Cardiovasc Drugs. 2012 Jun 1;12(3):143-56. doi: 10.2165/11599040-000000000-00000. Review.</citation>
    <PMID>22540323</PMID>
  </reference>
  <reference>
    <citation>Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13):1318-27. doi: 10.1016/j.jacc.2009.10.061. Review.</citation>
    <PMID>20338492</PMID>
  </reference>
  <reference>
    <citation>Wassertheurer S, Kropf J, Weber T, van der Giet M, Baulmann J, Ammer M, Hametner B, Mayer CC, Eber B, Magometschnigg D. A new oscillometric method for pulse wave analysis: comparison with a common tonometric method. J Hum Hypertens. 2010 Aug;24(8):498-504. doi: 10.1038/jhh.2010.27. Epub 2010 Mar 18.</citation>
    <PMID>20237499</PMID>
  </reference>
  <reference>
    <citation>Protogerou AD, Argyris A, Nasothimiou E, Vrachatis D, Papaioannou TG, Tzamouranis D, Blacher J, Safar ME, Sfikakis P, Stergiou GS. Feasibility and reproducibility of noninvasive 24-h ambulatory aortic blood pressure monitoring with a brachial cuff-based oscillometric device. Am J Hypertens. 2012 Aug;25(8):876-82. doi: 10.1038/ajh.2012.63. Epub 2012 Jun 7.</citation>
    <PMID>22673021</PMID>
  </reference>
  <reference>
    <citation>Sarafidis PA, Georgianos PI, Karpetas A, Bikos A, Korelidou L, Tersi M, Divanis D, Tzanis G, Mavromatidis K, Liakopoulos V, Zebekakis PE, Lasaridis A, Protogerou AD. Evaluation of a novel brachial cuff-based oscillometric method for estimating central systolic pressure in hemodialysis patients. Am J Nephrol. 2014;40(3):242-50. doi: 10.1159/000367791. Epub 2014 Oct 11.</citation>
    <PMID>25322847</PMID>
  </reference>
  <reference>
    <citation>Parati G, Stergiou G, O'Brien E, Asmar R, Beilin L, Bilo G, Clement D, de la Sierra A, de Leeuw P, Dolan E, Fagard R, Graves J, Head GA, Imai Y, Kario K, Lurbe E, Mallion JM, Mancia G, Mengden T, Myers M, Ogedegbe G, Ohkubo T, Omboni S, Palatini P, Redon J, Ruilope LM, Shennan A, Staessen JA, vanMontfrans G, Verdecchia P, Waeber B, Wang J, Zanchetti A, Zhang Y; European Society of Hypertension Working Group on Blood Pressure Monitoring and Cardiovascular Variability. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014 Jul;32(7):1359-66. doi: 10.1097/HJH.0000000000000221.</citation>
    <PMID>24886823</PMID>
  </reference>
  <reference>
    <citation>Weber T, Wassertheurer S, Rammer M, Maurer E, Hametner B, Mayer CC, Kropf J, Eber B. Validation of a brachial cuff-based method for estimating central systolic blood pressure. Hypertension. 2011 Nov;58(5):825-32. doi: 10.1161/HYPERTENSIONAHA.111.176313. Epub 2011 Sep 12.</citation>
    <PMID>21911710</PMID>
  </reference>
  <reference>
    <citation>Papaioannou TG, Argyris A, Protogerou AD, Vrachatis D, Nasothimiou EG, Sfikakis PP, Stergiou GS, Stefanadis CI. Non-invasive 24 hour ambulatory monitoring of aortic wave reflection and arterial stiffness by a novel oscillometric device: the first feasibility and reproducibility study. Int J Cardiol. 2013 Oct 25;169(1):57-61. doi: 10.1016/j.ijcard.2013.08.079. Epub 2013 Sep 8.</citation>
    <PMID>24063914</PMID>
  </reference>
  <reference>
    <citation>Franssen PM, Imholz BP. Evaluation of the Mobil-O-Graph new generation ABPM device using the ESH criteria. Blood Press Monit. 2010 Aug;15(4):229-31.</citation>
    <PMID>20658764</PMID>
  </reference>
  <reference>
    <citation>Wei W, Tölle M, Zidek W, van der Giet M. Validation of the mobil-O-Graph: 24 h-blood pressure measurement device. Blood Press Monit. 2010 Aug;15(4):225-8. doi: 10.1097/MBP.0b013e328338892f.</citation>
    <PMID>20216407</PMID>
  </reference>
  <reference>
    <citation>Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006 Nov;27(21):2588-605. Epub 2006 Sep 25.</citation>
    <PMID>17000623</PMID>
  </reference>
  <reference>
    <citation>Hametner B, Wassertheurer S, Kropf J, Mayer C, Eber B, Weber T. Oscillometric estimation of aortic pulse wave velocity: comparison with intra-aortic catheter measurements. Blood Press Monit. 2013 Jun;18(3):173-6. doi: 10.1097/MBP.0b013e3283614168.</citation>
    <PMID>23571229</PMID>
  </reference>
  <reference>
    <citation>Protogerou AD, Smulyan H, Safar ME. Closer to noninvasive out-of-office aortic blood pressure assessment: a time to think and act. Hypertension. 2011 Nov;58(5):765-7. doi: 10.1161/HYPERTENSIONAHA.111.177501. Epub 2011 Sep 12.</citation>
    <PMID>21911711</PMID>
  </reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2016</study_first_submitted>
  <study_first_submitted_qc>August 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2016</study_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Arterial Stiffness</keyword>
  <keyword>Aortic Pressure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

